Showing results (311-320 of 401) with videos related to
Sort By:
Pageof 41
Expert Review of Anticancer Therapy|May 25, 2016
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapyFrank C Passero, Dimitra Grapsa, Kostas N Syrigos, et al.Cancer Medicine Journal|November 16, 2020
Gastrointestinal Stromal Tumors Incidentalomas: A Case SeriesMina Ferig, Sylvia Alarcon Velasco, Layla Van Doren, et al.JOP : Journal of the Pancreas|May 7, 2011
Cutaneous metastasis in a patient with pancreatic cancerMuhammad Wasif Saif, Marianne Brennan, Robin Penney, et al.JOP : Journal of the Pancreas|March 13, 2012
Pancreatic neuroendocrine tumors: entering a new eraPaul E Oberstein, Helen Remotti, Muhammad Wasif Saif, et al.Expert Opinion on Drug Safety|December 25, 2018
The safety of lanreotide for neuroendocrine tumorAmandeep Godara, Nauman S Siddiqui, Margaret M Byrne, et al.Anti-Cancer Drugs|November 1, 2006
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to responseVladimir Gotlib, Samer Khaled, Igor Lapko, et al.Therapeutics and Clinical Risk Management|March 25, 2008
Hypokalemia secondary to capecitabine: a hidden toxicity?Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, et al.Cancer Medicine Journal|July 1, 2020
Consequences of the COVID-19 Pandemic on Cancer Clinical TrialsSally Flores, Nita Kurian, Anu Yohannan, et al.JOP : Journal of the Pancreas|July 17, 2012
New tools and novel approaches in treating locally advanced pancreatic adenocarcinomaWesam B Ahmed, John Ng, David E Wazer, et al.Cancer Medicine Journal|May 15, 2020
Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse EffectMuhammad Wasif Saif, Alicia Romano, Melissa H Smith, et al.Pageof 41